News
Why Idera Pharmaceuticals Inc. Jumped Higher Today
Idera Pharmaceuticals (NASDAQ: IDRA) is up 14% at 11:46 a.m. EST after releasing data from a phase 1/2 trial testing its drug candidate IMO-2125 in combination with Bristol-Myers Squibb's (NYSE:....
Healthcare: Is Valeant Pharmaceuticals the Turnaround Story of the Century?
This week, Valeant Pharmaceuticals (NYSE: VRX) reported its earnings, and the market rewarded it with a 17% stock price bump. While the company's shares are still down 95% from their 2016 highs,....
Here's Why the Best Is Yet to Come for Novavax, Inc.
Synthetic vaccine maker Novavax (NASDAQ: NVAX) has fallen on hard times. The dramatic failure of its closely watched respiratory syncytial virus fusion (RSV F) vaccine in elderly adults last year....
What You Need to Know From Inovio Pharmaceuticals' Q3 Update
Inovio Pharmaceuticals (NASDAQ: INO) continues to take investors on a roller coaster ride. The biotech stock was up close to 25% by late May, only to give up all of those gains and then some. A....
Editas Medicine Keeps Moving Forward
Editas Medicine (NASDAQ: EDIT) announced third-quarter 2017 results on Wednesday after the market closed, and shares of the CRISPR gene-editing specialist were down modestly on Thursday in....
Why Five Prime Therapeutics Stock Is on the Rebound Today
After a whopping 41% drop yesterday, shares of the clinical-stage biotech Five Prime Therapeutics (NASDAQ: FPRX) are on the mend today as the result of an upbeat clinical update. Specifically,....
The Bottom Line on Why Pacira Pharmaceuticals Inc. Rocketed Higher by as Much as 24%
Shares of Pacira Pharmaceuticals (NASDAQ: PCRX), which focuses on developing medicines to be used in the ambulatory or surgical setting, surged by as much as 24% during Wednesday's trading session....
Here's Why Editas Medicine Collapsed at Market Open Today
Shares of CRISPR gene-editing pioneer Editas Medicine (NASDAQ: EDIT) fell 12.1% shortly after the market opened Wednesday morning. Why? Although the company reported third-quarter 2017 earnings....
Why Spectrum Pharmaceuticals Stock Soared in October
Spectrum Pharmaceuticals (NASDAQ: SPPI), a small-cap oncology company, saw its shares gain a whopping 39.2% in October, according to S&P Global Market Intelligence. The drugmaker's stock took....
Despite FDA OK, Keryx Sinks on Gross-to-Net Surprise
Keryx Pharmaceuticals' (NASDAQ: KERX) Auryxia just won the Food and Drug Administration (FDA) green light for boosting iron levels in non-dialysis chronic kidney disease patients, but shares....
Why Neos Therapeutics Inc Rose 13.7% In October
Shares of Neos Therapeutics (NASDAQ: NEOS), a small-cap pharmaceutical company focused on attention deficit hyperactivity disorder (ADHD), jumped 13.7% in October according to data from S&P....
Why Inovio Pharmaceuticals Stock Sank in October
According to S&P Global Market Intelligence, shares of the DNA vaccine maker Inovio Pharmaceuticals (NASDAQ: INO) shed 8% of their value last month. On the bright side, this high single-digit....
Why Supernus Pharmaceuticals Inc. Is Having a Rather Non-Super Day
Shares of Supernus Pharmaceuticals (NASDAQ: SUPN), a developer of drugs that target diseases of the central nervous system, plunged as much as 19% during Tuesday's trading session following the....
The Big Reason ImmunoGen, Inc. Shed 24% of Its Value in October
Shares of ImmunoGen (NASDAQ: IMGN), a small-cap biotech company focused on the development of antibody-drug conjugates for the treatment of cancer, plunged 24% in October, according to data from....
Here's Why Advanced Accelerator Application SA Rose 20% in October
Shares of Advanced Accelerator Application SA (NASDAQ: AAAP), a manufacturer of tracers used for medical imaging, rose 19.8% in October according to data from S&P Global Market Intelligence. A....
Why AVEO Pharmaceuticals, Inc. Tanked 18.6% in October
Shares of AVEO Pharmaceuticals (NASDAQ: AVEO), a small-cap biopharma focused on cancer, fell 18.6% in October, according to data from S&P Global Market Intelligence. There doesn't appear to be....
Keryx Biopharmaceuticals, Inc. Fell 8.6% In October -- Here's Why That Doesn't Matter
Shares of Keryx Biopharmaceuticals (NASDAQ: KERX), a commercial-stage biopharma focused on kidney disease, fell 8.6% in October according to data from S&P Global Market Intelligence. However,....
Here's Why Stemline Therapeutics Inc. Jumped 23% Higher in October
Shares of Stemline Therapeutics Inc. (NASDAQ: STML), a clinical-stage biotech developing therapies that target cancer stem cells, shot up 23% in October according to data from S&P Global....
3 Stocks Changing the Future of Healthcare
The healthcare sector is in the midst of an unprecedented technological boom at the moment. Despite major advancements across several medical fields, though, this innovation bonanza is, quite....
Why Investors Should Be Excited About Corcept Therapeutics Plunging as Much as 18%
Shares of Corcept Therapeutics (NASDAQ: CORT), a California-based drug developer that focuses on treating severe metabolic, oncologic, and psychiatric diseases, tumbled as much as 18% during....
Here's Why Idera Pharmaceuticals Jumped as Much as 11.5% Today
Shares of clinical-stage biopharma Idera Pharmaceuticals (NASDAQ: IDRA) jumped over 11% today without any company-specific news. Why? The two leading RNA-based genetic medicine companies were....
Here's Why Intellia Therapeutics Sank as Much as 17.7% Today
Shares of CRISPR gene-editing biopharma Intellia Therapeutics (NASDAQ: NTLA) dropped nearly 18% today after the company announced a major public share offering to increase its cash balance. The....
Why ImmunoGen, Inc. Got Burned into ASH Today
ImmunoGen (NASDAQ: IMGN) closed down 12.6% on Wednesday, following the release of abstracts for the American Society of Hematology (ASH) meeting next month.The data covers a pair of ImmunoGen's....
Here's Why It's Oca-Liftoff for Intercept Pharmaceuticals Inc.
Shares of Intercept Pharmaceuticals (NASDAQ: ICPT), a small-cap biotech company focused on the development of drugs to treat an assortment of liver diseases, vaulted higher by as much as 10% on....
What's Causing Adamas Pharmaceuticals to Spike Higher Today
After a leading hedge fund reported it bought shares last month and in the wake of industry watcher upgrades, shares in Adamas Pharmaceuticals (NASDAQ: ADMS) rallied more than 10% higher earlier....